Recognition of shared melanoma antigen by HLA-A2-restricted cytolytic T cell clones derived from human tumor-infiltrating lymphocytes - PubMed (original) (raw)
Recognition of shared melanoma antigen by HLA-A2-restricted cytolytic T cell clones derived from human tumor-infiltrating lymphocytes
C Viret et al. Eur J Immunol. 1993 Jan.
Abstract
Three melanoma-specific cytotoxic T lymphocytes (CTL) clones were derived from the tumor-infiltrating lymphocyte (TIL) of human melanoma M17, and were used to study the expression of immunogenic melanoma peptides on allogeneic tumors. Antibody inhibition studies showed that two of these TIL clones were restricted by an HLA-A2 molecule which was identified as A2.1 by gene sequencing. The third CTL clone was not restricted by HLA-A2, but by a B or C HLA antigen. HLA-A2-restricted CTL clones M17-1 and M17-2 lysed 5 and 12 out of 15 HLA-A2+ allogeneic melanomas, respectively. Since they did not lyse autologous Epstein-Barr virus B cells, HLA-A2.1-transfected P815 cells, 13 HLA-A2+ non-melanoma tumor cell lines and 10 HLA-A2- melanomas, these clones appeared specific for melanoma-restricted epitopes presented by the HLA-A2.1 molecule. We then tried to determine why a few HLA-A2+ melanomas were refractory to TIL lysis. By using a combination of flow cytometry analysis, partial cloning and sequencing of their HLA-A2 genes, we show that failure to lyse did not result from low expression or polymorphism of the HLA-A2 molecule, or from deficient expression of the adhesion molecules ICAM-1 and LFA-3 by these melanomas. Taken together, our data confirm at the clonal level the existence of shared melanoma antigens recognized by TIL in the HLA-A2.1 context. They further show that individual peptides derived from these antigens are expressed by a large majority of HLA-A2+ melanomas. Identification of such peptides appears crucial for the future of vaccination therapies.
Similar articles
- Shared human melanoma antigens. Recognition by tumor-infiltrating lymphocytes in HLA-A2.1-transfected melanomas.
Kawakami Y, Zakut R, Topalian SL, Stötter H, Rosenberg SA. Kawakami Y, et al. J Immunol. 1992 Jan 15;148(2):638-43. J Immunol. 1992. PMID: 1729379 - Identification of human melanoma peptides recognized by class I restricted tumor infiltrating T lymphocytes.
Storkus WJ, Zeh HJ 3rd, Maeurer MJ, Salter RD, Lotze MT. Storkus WJ, et al. J Immunol. 1993 Oct 1;151(7):3719-27. J Immunol. 1993. PMID: 7690811 - Common expression of melanoma tumor-associated antigens recognized by human tumor infiltrating lymphocytes: analysis by human lymphocyte antigen restriction.
Hom SS, Topalian SL, Simonis T, Mancini M, Rosenberg SA. Hom SS, et al. J Immunother (1991). 1991 Jun;10(3):153-64. J Immunother (1991). 1991. PMID: 1868040 - T-cell recognition of human melanoma antigens.
Kawakami Y, Nishimura MI, Restifo NP, Topalian SL, O'Neil BH, Shilyansky J, Yannelli JR, Rosenberg SA. Kawakami Y, et al. J Immunother Emphasis Tumor Immunol. 1993 Aug;14(2):88-93. doi: 10.1097/00002371-199308000-00002. J Immunother Emphasis Tumor Immunol. 1993. PMID: 8280705 Free PMC article. Review. - Recognition of shared melanoma antigens by human tumor-infiltrating lymphocytes.
Topalian SL, Hom SS, Kawakami Y, Mancini M, Schwartzentruber DJ, Zakut R, Rosenberg SA. Topalian SL, et al. J Immunother (1991). 1992 Oct;12(3):203-6. doi: 10.1097/00002371-199210000-00013. J Immunother (1991). 1992. PMID: 1445813 Review.
Cited by
- alpha v beta3-dependent cross-presentation of matrix metalloproteinase-2 by melanoma cells gives rise to a new tumor antigen.
Godefroy E, Moreau-Aubry A, Diez E, Dreno B, Jotereau F, Guilloux Y. Godefroy E, et al. J Exp Med. 2005 Jul 4;202(1):61-72. doi: 10.1084/jem.20042138. J Exp Med. 2005. PMID: 15998788 Free PMC article. - A mutated HLA-A2 molecule recognized by autologous cytotoxic T lymphocytes on a human renal cell carcinoma.
Brändle D, Brasseur F, Weynants P, Boon T, Van den Eynde B. Brändle D, et al. J Exp Med. 1996 Jun 1;183(6):2501-8. doi: 10.1084/jem.183.6.2501. J Exp Med. 1996. PMID: 8676070 Free PMC article. - Suboptimal activation of melanoma infiltrating lymphocytes (TIL) due to low avidity of TCR/MHC-tumor peptide interactions.
Gervois N, Guilloux Y, Diez E, Jotereau F. Gervois N, et al. J Exp Med. 1996 May 1;183(5):2403-7. doi: 10.1084/jem.183.5.2403. J Exp Med. 1996. PMID: 8642353 Free PMC article. - A peptide recognized by human cytolytic T lymphocytes on HLA-A2 melanomas is encoded by an intron sequence of the N-acetylglucosaminyltransferase V gene.
Guilloux Y, Lucas S, Brichard VG, Van Pel A, Viret C, De Plaen E, Brasseur F, Lethé B, Jotereau F, Boon T. Guilloux Y, et al. J Exp Med. 1996 Mar 1;183(3):1173-83. doi: 10.1084/jem.183.3.1173. J Exp Med. 1996. PMID: 8642259 Free PMC article. - Culture of tumour-infiltrating lymphocytes from melanoma and colon carcinoma: removal of tumour cells does not affect tumour-specificity.
Mulder WM, Stukart MJ, Roos M, van Lier RA, Wagstaff J, Scheper RJ, Bloemena E. Mulder WM, et al. Cancer Immunol Immunother. 1995 Nov;41(5):293-301. doi: 10.1007/BF01517217. Cancer Immunol Immunother. 1995. PMID: 8536275 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous